Panel Discussion: With Unprecedented Phase III Progress & Expected Regulatory Feedback on Submissions, What Direction is Provided for the Dry AMD/GA Field?

Time: 4:45 pm
day: Day One


  • How can drug developers cut to the real barriers, and debate what is truly required to break through to
    successful treatments for dry-AMD?
  • Discuss how slow disease progression and a less than ideal endpoint measurement method lead to
    clinical trials that are necessarily large, lengthy and expensive
  • Examine how innovations in clinical trials with novel endpoints, non-traditional study designs and the
    use of surrogate diseases, developers can reduce the patient sample size and consequently lower the
    budget of clinical trials